Daily Stock Analysis, ASND, Ascendis Pharma A/S, priceseries

Ascendis Pharma A/S. Daily Stock Analysis
Stock Information
Open
115.11
Close
118.89
High
120.33
Low
113.83
Previous Close
114.89
Daily Price Gain
4.00
YTD High
133.96
YTD High Date
Jun 3, 2019
YTD Low
59.58
YTD Low Date
Jan 3, 2019
YTD Price Change
54.05
YTD Gain
83.36%
52 Week High
133.96
52 Week High Date
Jun 3, 2019
52 Week Low
53.20
52 Week Low Date
Nov 14, 2018
52 Week Price Change
49.73
52 Week Gain
71.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
22.19
Mar 14. 2017
28.66
24 Trading Days
29.14%
Link
LONG
Jan 5. 2018
39.92
Jan 30. 2018
51.77
16 Trading Days
29.68%
Link
LONG
Jan 4. 2019
64.62
Jan 28. 2019
71.28
15 Trading Days
10.31%
Link
Company Information
Stock Symbol
ASND
Exchange
NasdaqGS
Company URL
http://www.ascendispharma.com
Company Phone
45 36 94 44 86
CEO
Michael Wolff Jensen
Headquarters
-
Business Address
TUBORG BOULEVARD 5, HELLERUP, DENMARK DK-2900
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001612042
About

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies to address markets with unmet medical needs. The company was founded by Jan Møller Mikkelsen in September 2006 and is headquartered in Hellerup, Denmark.

Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.